Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 753-763
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.753
Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia
Kirvis Torres-Poveda, Margarita Bahena-Román, Claudia Madrid-González, Ana I Burguete-García, Víctor Hugo Bermúdez-Morales, Oscar Peralta-Zaragoza, Vicente Madrid-Marina
Kirvis Torres-Poveda, Margarita Bahena-Román, Claudia Madrid-González, Ana I Burguete-García, Víctor Hugo Bermúdez-Morales, Oscar Peralta-Zaragoza, Vicente Madrid-Marina, Chronic Infection and Cancer Division, Research Center on Infectious Diseases, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Morelos, Mexico
Author contributions: Torres-Poveda K and Madrid-Marina V participated in the design of the review and drafted the manuscript; Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH and Peralta-Zaragoza O participated in the redaction of results previous for this review; Bermúdez-Morales VH participated in the design of figure 1; all authors read and approved the final manuscript.
Supported by The Instituto Nacional de Salud Pública, Mexico; and by the grant from CONACYT-FOSISS SALUD-2008-C01-494 87701, Mexico
Correspondence to: Vicente Madrid-Marina, MD, PhD, Chronic Infection and Cancer Division, Research Center on Infectious Diseases, Instituto Nacional de Salud Pública, Avenida Universidad 655, Col. Santa María Ahuacatitlán, 62100 Cuernavaca, Morelos. Mexico. vmarina@insp.mx
Telephone: +52-777-3293056 Fax: +52-777-3293056
Received: December 28, 2013
Revised: April 5, 2014
Accepted: May 16, 2014
Published online: October 10, 2014
Processing time: 216 Days and 3 Hours
Abstract

Cervical cancer is a worldwide disease that constitutes a significant public health problem, especially in developing countries, not only due to its high incidence but also because the most affected population comprises women who belong to marginalized socio-economic classes. Clinical and molecular research has identified immunological impairment in squamous intraepithelial cervical lesions and cervical cancer patients. Human Papillomavirus (HPV) has several mechanisms for avoiding the immune system: it down-regulates the expression of interferon and upregulates interleukin (IL)-10 and transforming growth factor (TGF)-β1 to produce a local immunosuppressive environment, which, along with altered tumor surface antigens, forms an immunosuppressive network that inhibits the antitumor immune response. In this review we analyzed the available data on several deregulated cellular immune functions in patients with NIC I, NIC II and NIC III and cervical cancer. The effects of immunosuppressive cytokines on innate immune response, T-cell activation and cellular factors that promote tumor cell proliferation in cervical cancer patients are summarized. We discuss the functional consequences of HPV E2, E6, and E7 protein interactions with IL-10 and TGF-β1 promoters in the induction of these cytokines and postulate its effect on the cellular immune response in squamous intraepithelial cervical lesions and cervical cancer patients. This review provides a comprehensive picture of the immunological functions of IL-10 and TGF-β1 in response to HPV in humans.

Keywords: Cervical cancer; Immunosuppression; Interleukin-10; Transforming growth factor-β1; Human Papillomavirus

Core tip: Human Papillomavirus (HPV) persistence is a key event for cervical cancer development. HPV proteins E2, E6 and E7 induce the transcription of immunosuppressive cytokines as a means of evading HPV the host immune system. We postulate that interleukin-10 and transforming growth factor-β1 induce HPV immune system evasion through an immunosuppressive state in the local microenvironment of the cervix in HPV-infected women. These findings allow us to gain insight in our understanding of how HPV persist in the cervix and favor cervical lesions and cancer development, with potentially strong impact on vaccine development and the design of new targeted immunotherapies for women with cervical neoplasia.